Early recurrence and outcome determinants in NF1-associated malignant peripheral nerve sheath tumors: A single-center retrospective analysis.

A Anastasia Alekseevna Tararykova (N.N.Blokhin Russian Cancer Research Center, Moscow, Russian Federation) A Aslan K. Valiev (Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation) B Beniamin YURIKOVICH Bokhyan (Russia Cancer Research Center, Moscow, Russian Federation) K K Borzov (Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation) A A Salkov (Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation) M M Khachaturov (Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation) D Denis Sofronov (N.N. Blokhin Cancer Center, Moscow, Russian Federation) A Andrei A. Konev (Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation)

Abstract

e23563 Background: Malignant peripheral nerve sheath tumors (MPNST) are rare but highly aggressive malignancies in patients with neurofibromatosis type 1 (NF1). Compared with sporadic MPNST, NF1-associated tumors are characterized by earlier onset, biological heterogeneity, and poor local disease control. Real-world data on recurrence patterns, metastatic disease, and prognostic factors in this population remain limited. Methods: We performed a retrospective single-center analysis of 12 adult patients with NF1-associated MPNST treated between 2022 and 2025. Clinical, pathological, and treatment-related variables were collected. Recurrence-free survival (RFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Associations between clinicopathologic factors and outcomes were assessed using non-parametric and exact statistical tests ( p < 0.05). Results: Median age was 36 years (Q1–Q3: 31.0–46.5). High-grade tumors accounted for 58.3% of cases. Distant metastases at diagnosis were present in 25.0%. Median tumor size was 10.5 cm (Q1–Q3: 6.35–13.25). A high rate of early recurrence was observed, with 58.3% of patients developing relapse. Median RFS was 15 months (95% CI: 4–22), and recurrence risk increased from 20.5% at 5 months to 81.8% at 20 months, indicating early postoperative disease failure. Metastatic status was strongly associated with mortality: 100% of deaths occurred in patients with distant metastases ( p = 0.045). Recurrence occurred exclusively in patients without metastases, reflecting competing-risk dynamics in this small cohort. No significant associations were identified between recurrence and tumor size, grade, resection margins, chemotherapy, or tumor localization. A non-significant trend toward an association between higher grade and positive resection margins was observed ( p = 0.076). Median OS was not reached; estimated 5-year OS was 82.5% (95% CI: 46.1–95.3). Conclusions: NF1-associated MPNST is characterized by a high risk of early postoperative recurrence, representing a major clinical challenge. Metastatic disease emerged as the clearest determinant of mortality, while conventional clinicopathologic factors showed limited prognostic value. These findings highlight the need for larger NF1-MPNST cohorts and direct comparison with sporadic MPNST to better define biological differences, refine risk stratification, and guide translational and surveillance strategies.

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (8)

A

Anastasia Alekseevna Tararykova

N.N.Blokhin Russian Cancer Research Center, Moscow, Russian Federation

A

Aslan K. Valiev

Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation

B

Beniamin YURIKOVICH Bokhyan

Russia Cancer Research Center, Moscow, Russian Federation

K

K Borzov

Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation

A

A Salkov

Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation

M

M Khachaturov

Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation

D

Denis Sofronov

N.N. Blokhin Cancer Center, Moscow, Russian Federation

A

Andrei A. Konev

Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation